<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04168788</url>
  </required_header>
  <id_info>
    <org_study_id>49RC19_0197</org_study_id>
    <nct_id>NCT04168788</nct_id>
  </id_info>
  <brief_title>Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL</brief_title>
  <acronym>MVO</acronym>
  <official_title>Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic Veno-occlusive Disease in Children With Nephroblastoma or Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic veno-occlusive diseases (VOD) during cancer treatment in children are serious
      toxicities that have occurred with interruptions of chemotherapy and risk of relapse. In
      addition, these toxicities have a negative impact on the patient's quality of life, serious
      long-term sequelae and are potentially fatal in children.

      The risk factors associated with the occurrence of these complications are, to date, unknown,
      at the exception to the exposition to certain treatments (6-thioguanine, busulfan,
      actinomycin D, radiotherapy, etc.). To understand the effects of this toxicity and those of
      susceptibility to the disease becomes a major issue in the treatment of these children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Case-control study, nested in two French multicenter cohorts, on pharmacognenetic, biological
      and clinical susceptibility factors associated with the occurrence of hepatic veno-occlusive
      disease during the anticancer treatment for nephroblastoma or acute lymphoblastic leukemia,
      with centralized genetic analysis.

      After obtaining consent (patient or parents for minor patients), a blood sample is collected
      during the routine follow-up consultation and tubes are sent directly to Paris for the
      pharmacogenetic analysis at the end of the study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlate pharmacogenetic analysis with veno-occlusive disease.</measure>
    <time_frame>One day</time_frame>
    <description>Illumina's &quot;Human Omni2.5-8 v1.3&quot; microarrays explore more than 2,600,000 genetic variants, thus covering the entire genome with more than 300,000 genetic biomarkers in exons.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant characteristics.</measure>
    <time_frame>One day</time_frame>
    <description>Age, sociodemographics, personal and cancer history.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatic Veno-Occlusive Disease</condition>
  <condition>Nephroblastoma</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Nephrobalstoma or ALL</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pateints treated for a nephrobalstoma or ALL in childhood or adolescence</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test for genetic analysis</intervention_name>
    <description>Drawing blood to realize a genetic analysis for susceptibility to hepatic VOD.</description>
    <arm_group_label>Nephrobalstoma or ALL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged &lt; 18 years old at the time of cancer diagnosis

          -  Having been treated with a single line of treatment for nephroblastoma or ALL, in
             France between 2000 and 2018, and who did not receive allogeneic hematopoietic stem
             cell transplantation

          -  Weight greater than 5 kg at inclusion

          -  Informed consent dated and signed by the holder of the parental authority (if minor)
             or by the patient (if major) to take part in the study

          -  Affiliated to a Social Security scheme

        Exclusion Criteria:

          -  Unavaibility of constitutional DNA

          -  Person who receive more than one treatment line for nephroblastoma or ALL in childhood
             or adolescence

          -  Pregnant, lactating or parturient women

          -  Person deprived of their liberty by judicial or administrative decision

          -  Person under psychiatric care under duress

          -  Person subject to legal protection

          -  Person unable to express their consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Pellier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Angers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denise Jolivot, MD</last_name>
    <phone>33-(0)2-41-35-58-08</phone>
    <email>DeJolivot@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sybille Lazareff, CRA</last_name>
    <phone>33-(0)2-41-35-33-42</phone>
    <email>SyLazareff@chu-angers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Univesity Hostipal of Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Lutun, MD</last_name>
      <email>lutun.anne@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Liana Carausu, MD</last_name>
      <email>liana.carausu@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Claire Briandet, MD</last_name>
      <email>claire.briandet@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Hélène Sudour-Bonnange, MD</last_name>
      <email>h-sudour@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Arnauld Verschuur, MD</last_name>
      <email>Arnauld.VERSCHUUR@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Caroline Thomas, MD</last_name>
      <email>caroline.thomas@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nice</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Joy Benabida, MD</last_name>
      <email>Benadiba.j@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lauriane Lemelle, MD</last_name>
      <email>lauriane.lemelle@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Virginie Gandemer, MD</last_name>
      <email>virginie.gandemer@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of La Réunion</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yves Reguerre, MD</last_name>
      <email>yves.reguerre@chu-reunion.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pascale Blouin, MD</last_name>
      <email>p.blouin@chu-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Dominique Valteau-Couanet, MD</last_name>
      <email>dominique.valteau@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
    <mesh_term>Hepatic Veno-Occlusive Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

